Abstract Number: 2286 • 2019 ACR/ARP Annual Meeting
Mobile Responsive App – Useful Additional Tool for Data Collection in the German Pregnancy Register Rhekiss?
Background/Purpose: The German pregnancy register Rhekiss is designed as a nationwide, web-based longitudinal observational register established in 2015. The register follows women with inflammatory rheumatic…Abstract Number: 2373 • 2019 ACR/ARP Annual Meeting
Two Decades of Changes in RA Treatment and Disease Outcomes from the United States
Background/Purpose: RA causes significant morbidity and mortality. Over the last two decades, several new medications and strategies for treating RA earlier and more aggressively have…Abstract Number: 2477 • 2019 ACR/ARP Annual Meeting
Burden of Disease at Treatment Initiation Among Biologic-Naïve Patients with Oligoarticular versus Polyarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Background/Purpose: Oligoarticular PsA accounts for ≈50% of PsA worldwide, but only a paucity of data describes disease burden among these patients. The Corrona PsA/SpA Registry,…Abstract Number: 2722 • 2019 ACR/ARP Annual Meeting
The down Syndrome Arthropathy Cohort in the New Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: Clinical Characteristics, Treatment and Outcomes
Background/Purpose: Down syndrome arthropathy (DA) is under-recognized with a 19-month average delay in diagnosis (1). The majority present with polyarticular, rheumatoid factor (RF) and anti-nuclear…Abstract Number: 2850 • 2019 ACR/ARP Annual Meeting
Exploring Heterogeneity in Rheumatoid Arthritis: Outcomes up to 4 Years of Follow-Up in Patient Clusters Identified by Data-driven Analysis of the BRASS Registry
Background/Purpose: Patients with rheumatoid arthritis (RA) may share characteristics that relate to their future outcomes. We investigated clinical outcomes over a 4-year follow-up period in…Abstract Number: 2908 • 2019 ACR/ARP Annual Meeting
Remission in Patients with Rheumatoid Arthritis Receiving Triple Therapy Compared to Biological Therapy – A Swedish Nationwide Register Study
Background/Purpose: Current treatment guidelines for rheumatoid arthritis (RA) recommend a treat-to-target approach with early treatment initiation of disease-modifying antirheumatic drugs (DMARDs), most commonly methotrexate (MTX),…Abstract Number: 183 • 2019 ACR/ARP Annual Meeting
Exploring Heterogeneity in Rheumatoid Arthritis: Patient Profiling Through Principal Component and Cluster Analysis of the BRASS Registry
Background/Purpose: Data-driven principal component (PC) and cluster analysis has the potential to identify previously unknown patient subgroups within a rheumatoid arthritis (RA) registry to establish…Abstract Number: 432 • 2019 ACR/ARP Annual Meeting
Does Improvement in Patient Pain and Fatigue Lag Behind Clinical Remission in Rheumatoid Arthritis Patients? Data from a Rheumatoid Arthritis Registry
Background/Purpose: Rheumatoid arthritis (RA) patients are often not in remission due to patient global assessment of disease activity (PtGA) which is included in the formula…Abstract Number: 1417 • 2019 ACR/ARP Annual Meeting
Long-Term Effectiveness and Safety of Infliximab, Golimumab and Golimumab-IV in Rheumatoid Arthritis Patients from a Prospective Observational Registry
Background/Purpose: Long-term registries are essential to evaluate new therapies in a patient population that differs from clinical trials and usually varies over time. The purpose was…Abstract Number: 1418 • 2019 ACR/ARP Annual Meeting
Predictors of Response, Adverse Events and Treatment Retention in RA Patients Treated with Either Subcutaneous- or Intravenous- Golimumab in a Prospective, Observational Registry
Background/Purpose: The Biologic Treatment Registry Across Canada (BioTRAC) was a prospective, observational registry that enrolled rheumatoid arthritis (RA) patients treated with either subcutaneous golimumab (GLM-SC)…Abstract Number: 1481 • 2019 ACR/ARP Annual Meeting
Real-World Use of Apremilast in Combination with Biologic Therapy in Patients with Psoriatic Arthritis: Findings from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, demonstrated efficacy in adult patients with active PsA despite prior use of csDMARDs and/or biologics in phase…Abstract Number: 1542 • 2019 ACR/ARP Annual Meeting
Long-Term Effectiveness and Safety of Infliximab and Golimumab in Ankylosing Spondylitis Patients from a Prospective Observational Registry
Background/Purpose: Long-term registries are essential to evaluate new therapies in a patient population that differs from clinical trial and usually varies over time. The purpose…Abstract Number: 215 • 2018 ACR/ARHP Annual Meeting
A Decade Earlier- Onset of Symptoms of RA in the Indian (Asian) Cohort Compared to Dutch Cohort: Based on Meteor, a Global Database
Background/Purpose: Reported symptom onset and diagnosis debut in rheumatoid arthritis (RA) patients may be influenced by environmental factors, genetics and gene-environmental interactions, but also by…Abstract Number: 274 • 2018 ACR/ARHP Annual Meeting
Socioeconomic Disparities in Disease Activity in Patients with Rheumatoid Arthritis
Background/Purpose: To develop a methodology for well-defined rheumatoid arthritis (RA) measurement as an outcome and provide a clear definition of social determinants related to disease…Abstract Number: 549 • 2018 ACR/ARHP Annual Meeting
Unmet Treat-to-Target Goals with Available Targeted Immunomodulators in the Management of Rheumatoid Arthritis: Real World Evidence from the Corrona Registry
Background/Purpose: Targeted immunomodulators (TIMs) have revolutionized the therapy of RA and made low disease activity (LDA) a realistic goal for patients. Given the multiple therapy…
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- 18
- Next Page »